Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05640752
Other study ID # 2022KY-024-01
Secondary ID 62206197TJWJ2022
Status Recruiting
Phase N/A
First received
Last updated
Start date March 31, 2023
Est. completion date March 2025

Study information

Verified date March 2024
Source Tianjin Chest Hospital
Contact Jia Zhou, MD
Phone +8615522485560
Email zhoujiawenzhang@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In daily clinical routine, the evaluation of new-onset and stable chest pain (SCP) suggestive of chronic coronary syndrome (CCS) remains a challenge for physicians. Although coronary computed tomography angiography (CCTA) seems to be the first-line cardiac imaging testing (CIT) according to the recommendations from current guidelines, the optimal diagnostic strategy to identify low risk patients who may derive minimal benefit from further CIT is the cornerstone of clinical management for SCP. Recently, different diagnostic strategies were provided to effectively defer unnecessary CIT, but few studies have prospectively determined the actual effect of applying these strategies in clinical practice. Therefore, the OPERATE study was designed to compare the effectiveness and safety of two proposed diagnostic strategies in identification of low risk individual who may derive minimal benefit from CCTA among patients with SCP suggestive of CCS in a pragmatic randomized controlled trial (RCT).


Description:

OPERATE trial was an investigator-initiated, multicenter, prospective, CCTA-based, 2-arm 1:1 parallel-group, double-blind and pragmatic RCT planned to include 800 subjects with SCP suggestive of CCS. Subjects were assigned randomly to two groups: 1) 2016 National Institutes for Clinical Excellence guidelines-determined diagnostic strategy (NICE strategy) and 2) 2019 European Society of Cardiology guidelines-determined diagnostic strategy (ESC strategy) The primary objective of OPERATE trial is to compare the rates of CCTA without obstructive CAD according to NICE and ESC strategy. The key secondary objective is to assess whether the two strategies have no significant difference in terms of major adverse cardiac events (MACE). The investigators hypothesize that when comparing with NICE strategy, ESC strategy which sequentially incorporated the ESC-PTP model with RF-CL model will decrease the probability of CCTA without obstructive CAD but not at the expense of safety and cost over a follow-up period of 1 year.


Recruitment information / eligibility

Status Recruiting
Enrollment 800
Est. completion date March 2025
Est. primary completion date March 31, 2024
Accepts healthy volunteers No
Gender All
Age group 30 Years to 90 Years
Eligibility Inclusion criteria 1. SCP or equivalenta suggestive of CCS and clinically stability 2. No history of CAD (prior myocardial infarction, CR or any CAD documented by previous CIT) 3. Age =30 years 4. Willing and able to provide informed consent Exclusion criteria 1. Prior CIT within 1 year prior to randomization 2. Clinically instability (e.g. cardiogenic shock, ACS, severe arrhythmias or NYHA III or IV heart failure) 3. Non-sinus rhythm 4. Concomitant participation in another clinical trial 5. Complex structural heart disease 6. Non-cardiac illness with life expectancy < 2 years 7. Allergy to iodinated contrast agent 8. Estimated glomerular filtration rate<60 ml/min/1.73m2 within 90 days 9. Body mass index >35kg/m2 10. Expressing a clear preference for undergoing CIT or not 11. Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
2019 ESC guideline-determined diagnostic strategy
ESC-PTP is calculated using age, sex and type of chest pain according to 2019 ESC guideline for the diagnosis and management of CCS and RF-CL is calculated using age, sex, type of chest pain, hypertension, dyslipidemia, diabetes, smoking and family history of CAD based on the publication of Winther et al., respectively. According to ESC strategy, subjects with ESC-PTP =5% are classified into low risk group and ones with ESC-PTP =15% are classified into high risk group. For subjects with ESC-PTP of 5%-15%, ones with RF-CL =15% are classified into high risk group and ones with RF-CL <15% are classified into low risk group. CCTA should be referred for a subject in high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
2016 NICE guideline-determined diagnostic strategy
For subjects assigned to NICE strategy, ones with nonanginal chest pain and normal ECG were classified into low risk group and ones with typical and atypical angina or nonanginal chest pain with abnormal ECG were classified into high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.

Locations

Country Name City State
China Beijing Chaoyang Hospital Beijing Beijing
China Hebei Petrochina Central Hospital Lanfang Hebei
China Tianjin Chest Hospital Tianjin
China Tianjin First Central Hospital Tianjin Tianjin

Sponsors (1)

Lead Sponsor Collaborator
Tianjin Chest Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other The health-related quality of life assessment (SAQ) Seattle Angina Questionnaire 1 year
Other The health-related quality of life assessment (EQ-5D) Visual-analogue scale of the European Quality of Life-5 Dimensions 1 year
Primary CCTA without obstructive CAD The summary of nonobstructive CAD, no sign of CAD and nondiagnostic result detected by CCTA according to each strategy Through the initial management, an average of 2-5 days
Secondary MACE All-cause death, myocardial infarction and hospitalization due to unstable angina. 1 year
Secondary All-cause death Any death. 1 year
Secondary Myocardial infarction Myocardial infarction was defined and classified as spontaneous or coronary procedure-related MI according to the Fourth Universal Definition of Myocardial Infarction. 1 year
Secondary Hospitalization due to unstable angina An hospitalization event in which the final diagnosis was myocardial ischemia. 1 year
Secondary Exposure to radiation All exposure to radiation related to CIT and other cardiovascular procedures. 1 year
Secondary Procedural complications All procedural complications related to CIT and other cardiovascular procedures. 1 year
Secondary Cumulative proportion of patients receiving other CITs 1 year
Secondary Cumulative proportion of patients receiving CR 1 year
Secondary Cumulative proportion of patients who had alteration in OMT based on results of CCTA Thtough the initial management, an average of 2-5 days
Secondary Proportion of normal CCTA Through the initial management, an average of 2-5 days
Secondary Proportion of necessary CCTA Through the initial management, an average of 2-5 days
See also
  Status Clinical Trial Phase
Recruiting NCT06185530 - SECURE Trial: Stress Echocardiography With Carotid Ultrasound vs Routine CT Coronary Angiography in Chronic Coronary Syndrome for Endpoints N/A
Recruiting NCT05117866 - Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study N/A
Recruiting NCT05727982 - Identification of Molecular Mechanisms of Coronary Instability in Homogeneous Subsets of Patients With Acute Coronary Syndromes for the Implementation of Precision Medicine
Completed NCT06464276 - Effectiveness and Tolerability of Trimetazidine 80mg Once Daily in Patients With Chronic Coronary Syndrome: The V-GOOD Study
Recruiting NCT03936504 - Efficacy and Mechanism of TCCRP in Patients With Chronic Coronary Syndrome Under Fusion Cardiac Rehabilitation Model N/A
Recruiting NCT05978089 - Effect of Yangxinshi Tablet on Exercise Tolerance in Patients With Chronic Coronary Syndrome(MET STUDY) Phase 4
Recruiting NCT05875311 - Telemonitoring System for Improving Continuity of Care in Patients With Chronic Coronary Syndrome (TELSINCORC) N/A
Recruiting NCT05865600 - Perfusion Estimation For Optimal Treatment Strategy in Chronic Coronary Syndrome N/A
Recruiting NCT06337461 - Computational mOdelliNg of myoCardial pERfusion to Improve ouTcome Prediction Based on cOronary Artery Stenosis and Atherosclerotic Plaque Burden Assessment by Computed Tomography
Recruiting NCT05635994 - Advanced Invasive Diagnosis for Patients With Chronic Coronary Syndromes Undergoing Coronary ANGIOgraphy (AID-ANGIO)
Recruiting NCT05583786 - Intracoronary ECG ST-segment Shift Remission Time During Reactive Coronary Hyperemia
Completed NCT05592535 - Outcomes With Fractional Flow Reserve in Chronic Coronary Syndrome
Recruiting NCT06255678 - Angio-based Final Functional Effect of PCI
Recruiting NCT06275399 - Comprehensive Assessment of Morphometric, Functional, Biomechanical and Biological Interactions Between Atherosclerotic Plaque and Platelets Within the Stenosed Coronary Artery
Not yet recruiting NCT06186336 - Feasibility of a Deep Learning-based Algorithm for Non-invasive Assessment of Vulnerable Coronary Plaque
Withdrawn NCT04738344 - Very Long Versus Overlapping Stents in Long Coronary Lesions N/A
Active, not recruiting NCT04135989 - Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES Phase 4
Recruiting NCT05674630 - Ticin for the Treatment of Coronary Lesions With Drug Eluting Ballons Phase 4
Recruiting NCT06171061 - Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome Phase 4
Recruiting NCT05379608 - Intermittent Hypoxic-hyperoxic Training in Patients With Cardiovascular Pathology After COVID-19 Infection. N/A